CUE insider trading
NasdaqCM HealthcareCue Biopharma, Inc.: insider trade history from SEC Form 4 filings.
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Company website: www.cuebiopharma.com
CUE insider activity at a glance
FilingIQ tracks 143 insider transactions for CUE in filings since Jan 19, 2018. The most recent transaction is dated Aug 13, 2026.
Across the full history, 45 open-market purchases
and 37 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CUE insider trades is 55.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CUE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CUE?
- FilingIQ tracks 143 Form 4 insider transactions for CUE (Cue Biopharma, Inc.), covering filings from Jan 19, 2018 onwards. 25 of those are dated within the last 90 days.
- Are CUE insiders net buyers or net sellers?
- Across the full Form 4 history for CUE, 45 transactions (31%) were open-market purchases and 37 (26%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CUE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CUE in?
- Cue Biopharma, Inc. (CUE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $25.56M.
Methodology & sources
Every CUE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.